GD-2 CAR-T (3rd generation) with iCaspase safety switch

3rd generation GD-2 CAR-T with iCaspase suicide switch · Baylor College of Medicine

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GD-2 CAR-T (3rd generation) with iCaspase safety switch, covering 2026-04-06 to 2026-04-06. Get the full timeline:

Most recent: Clinical Trial Update: 3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN [Phase 1]

See pricing